1.54
5.37%
0.05
Lixte Biotechnology Holdings Inc stock is traded at $1.54, with a volume of 1,131.
It is up +5.37% in the last 24 hours and down -18.23% over the past month.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
See More
Previous Close:
$1.49
Open:
$1.48
24h Volume:
1,131
Relative Volume:
0.00
Market Cap:
$3.40M
Revenue:
-
Net Income/Loss:
$-4.69M
P/E Ratio:
-0.4162
EPS:
-3.7
Net Cash Flow:
$-3.81M
1W Performance:
-1.88%
1M Performance:
-18.23%
6M Performance:
-36.95%
1Y Performance:
-45.10%
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Name
Lixte Biotechnology Holdings Inc
Sector
Industry
Phone
310 203 2902
Address
248 ROUTE 25A, EAST SETAUKET
Compare LIXT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
LIXT | 1.51 | 3.40M | 0 | -4.69M | -3.81M | -3.70 |
VRTX | 445.91 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 736.64 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 585.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.06 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.23 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
LIXTW (Lixte Biotechnology Holdings) Accounts Payable & Acc - GuruFocus.com
LIXT stock touches 52-week low at $1.53 amid market challenges - Investing.com Australia
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
LIXT stock touches 52-week low at $1.53 amid market challenges By Investing.com - Investing.com South Africa
Lixte Biotechnology granted extension to meet Nasdaq listing rules By Investing.com - Investing.com Australia
Lixte Biotechnology granted extension to meet Nasdaq listing rules - Investing.com
Lixte Biotechnology Holdings Inc WT (LIXTW-Q) QuotePress Release - The Globe and Mail
Omeros (OMER) Shares Drop 5.04% Amid Financial Struggles - GuruFocus.com
MRVI Stock Drops 5.11% Amid Financial Report Release - GuruFocus.com
Lixte Biotechnology (NASDAQ:LIXT) Stock Price Down 2.1% - Defense World
LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy - GlobeNewswire
Should investors be concerned about LYT’s high price-to-sales ratio? - US Post News
Lilium (NASDAQ:LILM) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Liquidia Co. (NASDAQ:LQDA) Shares Bought by Rhumbline Advisers - Defense World
Pacer Advisors Inc. Has $16.07 Million Stock Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World
Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex
Renaissance Technologies LLC Sells 2,000 Shares of LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Texas Permanent School Fund Corp Trims Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World
First Eagle Investment Management LLC Increases Stake in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Huber Capital Management LLC Acquires 241,814 Shares of Lyft, Inc. (NASDAQ:LYFT) - Defense World
Acadian Asset Management LLC Cuts Position in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Quest Partners LLC Invests $28,000 in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Investors who lost money with shares of Liquidia Corporation - openPR
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia CorporationLQDA - Kilgore News Herald
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Biotech Steals The Show Following Pre-Clinical Data Announcement - MSN
Lixte Biotechnology Holdings Inc (LIXT) Stock: A Year of Decreases and Increases - The InvestChronicle
LIXTLixte Biotechnology Holdings, Inc. Latest Stock News & Market Updates - StockTitan
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology - GlobeNewswire
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update - Defense World
Why Nordstrom Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Market Recap Check: Lixte Biotechnology Holdings Inc (LIXT)’s Positive Finish at 2.00, Up/Down 11.12 - The Dwinnex
LIXT Stock: A Voyage Through Lixte Biotechnology Holdings Inc’s Finances - The InvestChronicle
LIXT stock touches 52-week low at $1.55 amid market fluctuations - Investing.com
First Patient Dosed with LIXTE’s LB-100 in New Clinical - GlobeNewswire
First Patient Dosed with Lixte Biotechnology Holdings, Inc.?s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company - Marketscreener.com
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company - StockTitan
Lixte Biotechnology faces Nasdaq delisting over equity shortfall - Investing.com India
LIXT (Lixte Biotechnology Holdings) PS Ratio : (As of Aug. 20, 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) PS Ratio : (As of Aug. 19, 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
LIXTE Biotechnology Provides Update On Recent Activities and Developments - ForexTV.com
LIXT (Lixte Biotechnology Holdings) Purchase Of Investment : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Owner Earnings per Shar - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Debt-to-Equity : 0.00 (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Effective Interest Rate on Debt % : 0.00% (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Float Percentage Of Tot - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Interest Coverage : 0 (At Loss) (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Capex-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):